Skip to main content
B

bialoom

Bialoom develops silicon plasmo-photonic biosensors embedded in disposable cartridges for the rapid quantification of critical biomarkers from patient blood samples. This technology enables early diagnosis and treatment of acute infections at the point of care, addressing the need for timely and evidence-based medical interventions.

Founded 20187700+ followers
Updated 4 months ago

Funding

$547.6K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Problem

Rapid diagnosis and treatment of acute infections are often hindered by the need for complex laboratory equipment and time-consuming analysis. Traditional methods for quantifying critical biomarkers from patient blood samples can delay evidence-based medical interventions, especially at the point of care.

Solution

Bialoom is developing silicon plasmo-photonic biosensors embedded in disposable cartridges to enable rapid quantification of critical biomarkers from patient blood samples at the point of care. The company's solution leverages proprietary silicon plasmo-photonic biosensor technology to deliver affordable biochips. The multi-functional biochip is capable of quantifying complicated biomarker signatures from patient blood, facilitating faster and evidence-based diagnosis and treatment of severe infections. The biosensors utilize plasmonic interferometric sensors for sensitive detection of multiple critical biomarkers from small volumes of analyte, and standard semiconductor technology (CMOS) for low-cost volume manufacturing of the multi-sensor chip.

Target Audience

The primary target audience includes healthcare providers and medical professionals requiring rapid and accurate diagnostic tools for early diagnosis and treatment of acute infections at the point of care.

Features

  • Proprietary plasmonic interferometric sensors for highly sensitive detection
  • Capability to perform tests from picoliter-scale analytes
  • CMOS-based manufacturing for low-cost, high-volume production
  • Biochips embedded in disposable cartridges for ease of use
  • Multiplexing capabilities for quantifying complicated biomarker signatures
This profile is AI-generated and may contain inaccuracies.